Viking Therapeutics Faces Partnership Deadline as Market Anticipates Phase 3 Trials
PILLAR DIAGNOSTIC // WEEK 11
“A binding requirement for an external collaboration to initiate Phase 3 oral trials is colliding with aggressive growth expectations, and the market hasn’t yet priced in potential deal delays, setting up sharp downside if the partnership timeline slips.”
Proposed action
Avoid chasing new positions and consider hedging or trimming ahead of the partnership announcement.
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
VK2735, Viking’s dual GIPR/GLP-1 receptor agonist in both oral and subcutaneous forms, is on track for Phase III initiation in Q3 2026 amid a rapidly expanding obesity market, underpinned by a chronic weight-management pipeline and a cash and short-term investment balance of $706 million as of end-2025.
THE MAP
Structure & constraints
VKTX requires external collaboration to advance VK2735 into Phase 3 oral trials and the maintenance study, with Phase 3 set to commence in Q3 2026 and oral maintenance tolerability data expected later this year.
THE MOOD
Consensus & positioning
Bullish narratives center on VKTX’s dual GLP-1/GIP program as superior to tirzepatide, substantial undervaluation arguments from DCF models, insider buying, and planned Phase 3 momentum, fueling optimistic expectations for strong returns despite elevated trial hurdles and mixed growth ratings.